264 related articles for article (PubMed ID: 21613260)
1. Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.
Goto E; Tomita A; Hayakawa F; Atsumi A; Kiyoi H; Naoe T
Blood; 2011 Aug; 118(6):1600-9. PubMed ID: 21613260
[TBL] [Abstract][Full Text] [Related]
2. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.
Zhu G
Curr Pharm Biotechnol; 2013; 14(9):849-58. PubMed ID: 24433507
[TBL] [Abstract][Full Text] [Related]
3. The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
Lång E; Grudic A; Pankiv S; Bruserud O; Simonsen A; Bjerkvig R; Bjørås M; Bøe SO
Blood; 2012 Jul; 120(4):847-57. PubMed ID: 22692509
[TBL] [Abstract][Full Text] [Related]
4. Varying responses of PML-RARA with different genetic mutations to arsenic trioxide.
Liu J; Zhu HH; Jiang H; Jiang Q; Huang XJ
Blood; 2016 Jan; 127(2):243-50. PubMed ID: 26537301
[TBL] [Abstract][Full Text] [Related]
5. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein.
Isakson P; Bjørås M; Bøe SO; Simonsen A
Blood; 2010 Sep; 116(13):2324-31. PubMed ID: 20574048
[TBL] [Abstract][Full Text] [Related]
6. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
[TBL] [Abstract][Full Text] [Related]
7. Mutations at proximal cysteine residues in PML impair ATO binding by destabilizing the RBCC domain.
Dubey S; Mishra N; Shelke R; Varma AK
FEBS J; 2024 Apr; 291(7):1422-1438. PubMed ID: 38129745
[TBL] [Abstract][Full Text] [Related]
8. Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia.
Iaccarino L; Ottone T; Divona M; Cicconi L; Cairoli R; Voso MT; Lo-Coco F
Br J Haematol; 2016 Mar; 172(6):909-13. PubMed ID: 26728337
[TBL] [Abstract][Full Text] [Related]
9. Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
Lou Y; Ma Y; Sun J; Ye X; Pan H; Wang Y; Qian W; Meng H; Mai W; He J; Tong H; Jin J
Ann Hematol; 2015 Nov; 94(11):1829-37. PubMed ID: 26294332
[TBL] [Abstract][Full Text] [Related]
10. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure.
Ablain J; Rice K; Soilihi H; de Reynies A; Minucci S; de Thé H
Nat Med; 2014 Feb; 20(2):167-74. PubMed ID: 24412926
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.
Zhang XW; Yan XJ; Zhou ZR; Yang FF; Wu ZY; Sun HB; Liang WX; Song AX; Lallemand-Breitenbach V; Jeanne M; Zhang QY; Yang HY; Huang QH; Zhou GB; Tong JH; Zhang Y; Wu JH; Hu HY; de Thé H; Chen SJ; Chen Z
Science; 2010 Apr; 328(5975):240-3. PubMed ID: 20378816
[TBL] [Abstract][Full Text] [Related]
12. [Effects of all-trans retinoic acid and arsenic trioxide on tissue factor expression of acute promyelocytic leukemia cells].
Guo W; Wang H; Zhao W
Zhonghua Yi Xue Za Zhi; 2000 May; 80(5):327-31. PubMed ID: 11798779
[TBL] [Abstract][Full Text] [Related]
13. PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.
Bräuer-Hartmann D; Hartmann JU; Wurm AA; Gerloff D; Katzerke C; Verga Falzacappa MV; Pelicci PG; Müller-Tidow C; Tenen DG; Niederwieser D; Behre G
Cancer Res; 2015 Aug; 75(16):3411-24. PubMed ID: 26041820
[TBL] [Abstract][Full Text] [Related]
14. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
Sternsdorf T; Puccetti E; Jensen K; Hoelzer D; Will H; Ottmann OG; Ruthardt M
Mol Cell Biol; 1999 Jul; 19(7):5170-8. PubMed ID: 10373566
[TBL] [Abstract][Full Text] [Related]
15. All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene.
Strehl S; König M; Boztug H; Cooper BW; Suzukawa K; Zhang SJ; Chen HY; Attarbaschi A; Dworzak MN
Leukemia; 2013 Jul; 27(7):1606-10. PubMed ID: 23271512
[No Abstract] [Full Text] [Related]
16. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
[TBL] [Abstract][Full Text] [Related]
17. Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation.
Vitaliano-Prunier A; Halftermeyer J; Ablain J; de Reynies A; Peres L; Le Bras M; Metzger D; de Thé H
Blood; 2014 Dec; 124(25):3772-80. PubMed ID: 25258343
[TBL] [Abstract][Full Text] [Related]
18. Curing APL through PML/RARA degradation by As2O3.
Lallemand-Breitenbach V; Zhu J; Chen Z; de Thé H
Trends Mol Med; 2012 Jan; 18(1):36-42. PubMed ID: 22056243
[TBL] [Abstract][Full Text] [Related]
19. Requirement of PML SUMO interacting motif for RNF4- or arsenic trioxide-induced degradation of nuclear PML isoforms.
Maroui MA; Kheddache-Atmane S; El Asmi F; Dianoux L; Aubry M; Chelbi-Alix MK
PLoS One; 2012; 7(9):e44949. PubMed ID: 23028697
[TBL] [Abstract][Full Text] [Related]
20. Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.
Nasr R; de Thé H
Int J Hematol; 2010 Jun; 91(5):742-7. PubMed ID: 20455087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
